Stakeholders across the healthcare system are demanding proactive disease management and objective measurement of treatment efficacy. Accurate physiological assessments made at the point of care are intended to give doctors the information they need to actively manage their patients. The Transdermal GFR system is intended to be a key assessment tool that provides assessment data on kidney function (GFR) which could be helpful to doctors both in their role in treating patients as well as in their research.*
Application of the MediBeacon technology in gastroenterology is focused on developing a transdermal measurement of gastrointestinal permeability. Increased gut permeability has been proposed to be an indicator of gut inflammation, a primary target in the treatment of Inflammatory Bowel Disease. Initial clinical studies to determine the utility of MediBeacon fluorescent tracer agents in monitoring and possibly aiding in diagnosis of Crohn’s patients have been completed.*
MediBeacon technology is built upon focused areas of innovation. Novel fluorescent tracer agents and highly engineered transdermal sensors along with unique analytical approaches are focused on delivering systems which have the potential to have a positive impact on the quality and cost of patient care. The MediBeacon intellectual property portfolio includes granted composition of matter, algorithm, and method patents in the US, Europe and beyond.
Forward-Looking Statements
Statements on this website may include forward-looking statements within the meaning of certain securities laws, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended.
Forward-Looking Statements
Statements on this website may include forward-looking statements within the meaning of certain securities laws, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended.
These forward-looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words “may,” “will,” “could,” “should,” “would,” “suspect,” “outlook,” “believe,” “plan,” “anticipate,” “estimate,” “expect,” “intend,” “forecast,” “objective,” “hope,” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements.
By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. We caution readers not to place undue reliance on these statements as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to; the applicability of patents and proprietary technology; possible patent litigation; approval of products in the company’s pipeline; marketing of products; meeting projected development timelines and goals; product liability and insurance; dependence on strategic partnerships and licenses; concentration of the company’s revenue; substantial competition and rapid technological change in the industry; the publication of negative results of clinical trials of the company’s products; the ability to access capital; the ability to attract and retain key personnel; changes in government regulation or regulatory approval processes; dependence on contract research organizations; third party reimbursement; the success of the company’s strategic investments; the achievement of development goals and time frames; the possibility of shareholder dilution; market price volatility of securities; and the existence of significant shareholders.
We caution that the foregoing list of important factors that may affect future results is not exhaustive. When reviewing our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The information contained on this website is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this website should be read as applying to every other instance of such information appearing herein.
We do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.